Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.

Yu Z, He S, Wang D, Patel HK, Miller CP, Brown J, Hattersley G, Saeh JC.

Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017. doi: 10.1158/1078-0432.CCR-17-0670. [Epub ahead of print]

PMID:
28974548
2.

Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.

Tsourdi E, Lademann F, Ominsky MS, Rijntjes E, Köhrle J, Misof BM, Roschger P, Klaushofer K, Hofbauer LC, Rauner M.

Endocrinology. 2017 Nov 1;158(11):3765-3777. doi: 10.1210/en.2017-00247.

PMID:
28973221
3.

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.

Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J.

Rheumatol Ther. 2017 Aug 22. doi: 10.1007/s40744-017-0078-y. [Epub ahead of print]

4.

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.

McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.

Osteoporos Int. 2017 Oct;28(10):2967-2973. doi: 10.1007/s00198-017-4140-y. Epub 2017 Jul 26.

PMID:
28748386
5.

The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.

McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA.

J Bone Miner Res. 2017 Aug;32(8):1625-1631. doi: 10.1002/jbmr.3163. Epub 2017 Jun 26.

PMID:
28474780
6.

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models.

Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F.

Clin Cancer Res. 2017 Aug 15;23(16):4793-4804. doi: 10.1158/1078-0432.CCR-16-2561. Epub 2017 May 4.

PMID:
28473534
7.

Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).

Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G.

Regul Toxicol Pharmacol. 2017 Jun;86:356-365. doi: 10.1016/j.yrtph.2017.04.001. Epub 2017 Apr 4.

8.

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.

Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.

Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009.

9.

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.

Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.

Bone. 2017 Feb;95:143-150. doi: 10.1016/j.bone.2016.11.027. Epub 2016 Nov 25.

10.

Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

Moreira CA, Fitzpatrick LA, Wang Y, Recker RR.

Bone. 2017 Apr;97:314-319. doi: 10.1016/j.bone.2016.11.004. Epub 2016 Nov 5.

11.

One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.

Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G.

J Bone Miner Res. 2017 Jan;32(1):24-33. doi: 10.1002/jbmr.3003. Epub 2016 Oct 17.

PMID:
27748532
12.

Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.

Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM.

J Bone Miner Res. 2017 Jan;32(1):17-23. doi: 10.1002/jbmr.2991. Epub 2016 Sep 28.

PMID:
27612281
13.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Erratum in: JAMA. 2017 Jan 24;317(4):442.

PMID:
27533157
14.

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats.

Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G.

Calcif Tissue Int. 2016 Nov;99(5):489-499. Epub 2016 Jul 9.

15.

Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.

Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ.

Endocrinology. 2016 Jan;157(1):141-9. doi: 10.1210/en.2015-1726. Epub 2015 Nov 12.

16.

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.

PMID:
25393645
17.

Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats.

Jayaraman A, Christensen A, Moser VA, Vest RS, Miller CP, Hattersley G, Pike CJ.

Endocrinology. 2014 Apr;155(4):1398-406. doi: 10.1210/en.2013-1725. Epub 2014 Jan 15.

18.

Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.

Miller CP, Shomali M, Lyttle CR, O'Dea LS, Herendeen H, Gallacher K, Paquin D, Compton DR, Sahoo B, Kerrigan SA, Burge MS, Nickels M, Green JL, Katzenellenbogen JA, Tchesnokov A, Hattersley G.

ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. doi: 10.1021/ml1002508. eCollection 2011 Feb 10.

19.

Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs).

Miller CP, Bhaket P, Muthukaman N, Lyttle CR, Shomali M, Gallacher K, Slocum C, Hattersley G.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7516-20. doi: 10.1016/j.bmcl.2010.09.140. Epub 2010 Oct 7.

PMID:
21036041
20.

Strategic business planning and development for competitive health care systems.

Nauert RC.

J Health Care Finance. 2005 Winter;32(2):72-94.

PMID:
18975726

Supplemental Content

Loading ...
Support Center